All In Biotech

Drug Trial Radar · NCT06361537

Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

Prospective, Multicenter, Randomized, Double-blind, Parallel Group, Placebo- Controlled, Efficacy and Safety Phase 3 Study of an Intravenous Human Plasma- Derived C1 Esterase Inhibitor (C1-INH) Concentrate in Participants With Congenital C1-INH Deficiency for the Treatment and Pre-procedure Prevention of Acute Hereditary Angioedema Attacks

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 124 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

124

Planned (sponsor's estimate)

Start

Apr 30, 2024

Primary completion

Dec 2026

Study completion Jun 2027

Sponsor

Lead sponsor
OctapharmaIndustry
Sponsor type
Industry
First posted
Apr 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prospective, multicenter, randomized, double-blind, parallel group, placebo- controlled, efficacy and safety phase 3 study of an intravenous human plasma- derived C1 esterase inhibitor (C1-INH) concentrate in participants with congenital C1-INH deficiency for the treatment and pre-procedure prevention of acute hereditary angioedema attacks

Conditions

  • Acute Hereditary Angio Edema

Interventions

  • OCTA-C1-INHDrug

    OCTA-C1-INH is a stable, sterile, virus-inactivated, nano-filtered, highly purified concentrate of human C1-INH prepared from pooled human plasma. After reconstitution in 2.5mL water for injection, the solution can be administered as a slow IV injection. OCTA-C1-INH is given as a dose of 20 IU/kg body weight (BW)

  • PlaceboOther

    0.1 mL/kg BW 0.9% sodium chloride injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time (h) to beginning of unequivocal symptom relief at the defining site in blinded participants.Time frame: Within 4 hours after injection

Locations

29 sites in 14 countries. Site status is shown where the registry gives one.

  • Octapharma Research Site

    Centennial, Colorado · Withdrawn

  • Octapharma Research Site

    Farmington Hills, Michigan · Withdrawn

  • Octapharma Research Site

    Toledo, Ohio · Withdrawn

  • Octapharma Research Site

    Tirana, Albania · Withdrawn

  • Octapharma Research Site

    Rosario, Argentina · Recruiting

  • Octapharma Research Site

    Yerevan, Armenia · Recruiting

  • Octapharma Research Site

    Sofia, Bulgaria · Recruiting

  • Octapharma Research Site

    Bangalore, India · Not yet recruiting

  • Octapharma Research Site, Chhatrapati Sambhajinagar

    Chhatrapati Sambhajinagar, India · Not yet recruiting

  • Octapharma Research Site

    Hyderabad, India · Not yet recruiting

  • Octapharma Research Site

    Patna, India · Not yet recruiting

  • Octapharma Research Site

    Srinagar, India · Not yet recruiting

  • Octapharma Research Site

    Pune, Maharashtra, India · Not yet recruiting

  • Octapharma Research Site

    Almaty, Kazakhstan · Not yet recruiting

  • Octapharma Research Site

    Almaty, Kazakhstan · Not yet recruiting

  • Octapharma Research Site

    México, Mexico · Not yet recruiting

  • Octapharma Research Site

    Mexico City, Mexico · Not yet recruiting

  • Octapharma Research Site

    Podgorica, Montenegro · Withdrawn

  • Octapharma Research Site 5102

    Lima, Peru · Recruiting

  • Octapharma Research Site 5103

    Lima, Peru · Recruiting

  • Octapharma Research Site

    Cluj-Napoca, Romania · Withdrawn

  • Octapharma Research Site

    Kragujevac, Serbia · Withdrawn

  • Octapharma Research Site

    Ankara, Turkey (Türkiye) · Not yet recruiting

  • Octapharma Research Site

    Istanbul, Turkey (Türkiye) · Not yet recruiting

  • Octapharma Research Site

    Izmir, Turkey (Türkiye) · Withdrawn

  • Octapharma Research Site

    Sakarya, Turkey (Türkiye) · Not yet recruiting

  • Octapharma Research Site

    Kyiv, Ukraine · Recruiting

  • Octapharma Research Site

    Lviv, Ukraine · Withdrawn

  • Octapharma Research Site

    Lviv, Ukraine · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.